Hims & Hers Health vs. Teladoc Health: Which Healthcare Stock Is a Better Buy in 2026?

Hims & Hers is highlighted as a steadier growth engine, with FY 2025 revenue near $2.3B (+59%) and net income of about $128.4M (net margin ~5.5%), while Teladoc reported FY 2025 revenue around $2.5B (-1.5%) with a narrowed but still material net loss near -$200.3M (net margin ~-7.9%). The article flags key risks for Hims & Hers from potential FDA/DOJ/HHS scrutiny over compounded GLP-1s/peptides and operational risk from the pending Eucalyptus acquisition, while Teladoc faces customer concentration (top five ~19% of revenue) and competition pressures, despite a better liquidity profile (current ratio ~2.7x vs. ~1.9x for Hims & Hers). Valuation is mixed: Hims & Hers trades at a higher forward P/E (78.9x) and P/S (3.5x) versus Teladoc’s lower P/S (0.7x) and forward P/E (59.4x), leading the author to prefer Hims & Hers for 2026 despite regulatory overhangs.

Analysis

The cleanest read is not “growth vs value” but “policy risk vs distribution risk.” HIMS is still the higher-beta asset because the market is paying for subscription durability, yet a meaningful chunk of that growth is tied to products whose addressable market can shrink quickly if regulators tighten the definition of permissible compounding. That creates an asymmetric setup: upside from continued subscriber gains is linear, while downside from an FDA/DOJ adverse turn is sudden and multiple-compressing.

TDOC looks cheap for a reason: low valuation alone does not solve customer concentration or competitive encroachment from AMZN/GOOG, which can bundle virtual care into broader ecosystems and pressure pricing. The WMT channel matters more as a distribution test than a near-term earnings lever; if it drives lower acquisition cost and better engagement, it could stabilize revenue, but if it is just incremental traffic, it won’t re-rate the stock. Over 1-3 months, the market will likely keep rewarding any sign of HIMS monetization durability while treating TDOC as a turnaround that needs proof, not promises.

Contrarian view: consensus is probably overestimating how much of HIMS’s growth is structurally defensible and underestimating how much TDOC’s enterprise relationships cushion downside. If HIMS can show that non-GLP-1 cohorts are accelerating and gross margin holds despite regulatory noise, the stock can still work; if not, today’s premium becomes hard to justify. For TDOC, the thesis breaks if a major health-plan client rolls off or if BetterHelp deterioration re-accelerates; otherwise, the market may be underpricing a slow but real operating leverage story over 6-18 months.

Key Decisions for Investors

• Small long HIMS / short TDOC pair trade for 1-3 months: express a quality-vs-turnaround spread, but keep sizing modest because HIMS carries binary regulatory headline risk.
• If adding HIMS, prefer call spreads rather than outright equity for the next earnings/regulatory window; thesis is continuation of subscriber growth, falsified by any FDA action or DOJ/HHS escalation.
• Use TDOC as a watchlist short only on rallies into better-than-feared commentary; the short works best if client concentration or BetterHelp weakness reappears, but value alone is not a catalyst.
• For a lower-risk expression, buy WMT on any pullback only if virtual-care integration shows measurable engagement; otherwise treat the partnership as optionality, not a near-term earnings driver.
• Set an alert on HIMS regulatory headlines and TDOC client-retention commentary; if HIMS de-risks on product mix and TDOC shows stable large-account renewals, rotate out of the pair.